Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients

Journal of Gene Medicine

Volumn 13, Issue 5, 2011, Pages 253-261

  Raki, Mari ^a,b   Sarkioja, Merja ^a,b   Escutenaire, Sophie ^a,b   Kangasniemi, Lotta ^a,b   Haavisto, Elina ^a,b   Kanerva, Anna ^a,b   Cerullo, Vincenzo ^a,b   Joensuu, Timo ^c   Oksanen, Minna ^a,b   Pesonen, Sari ^a,b   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c International Comprehensive Cancer Center Docrates   (Finland)

Author keywords

Adenovirus; Cancer; Neutralizing antibodies; Oncolytic virotherapy

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS;

ADENOVIRUS 5; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FIBER; HUMAN; HUMAN CELL; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHUMAN; OUTCOME VARIABLE; PRIORITY JOURNAL; PROTEIN MOTIF; TREATMENT RESPONSE; VIRUS CAPSID; VIRUS NEUTRALIZATION;

ADENOVIRIDAE; ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; GENE THERAPY; GENETIC VECTORS; HUMANS; MIDDLE AGED; NEOPLASMS; ONCOLYTIC VIROTHERAPY; TREATMENT OUTCOME; YOUNG ADULT;

ADENOVIRIDAE; MIRIDAE;

EID: 79958140936     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1565     Document Type: Article

References (60)

1. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216.
2. Nemunaitis J. Live viruses in cancer treatment. Oncology (Williston Park) 2002; 16: 1483-1492.
3. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11: S10-S17.
4. Tsai V, Johnson DE, Rahman A, et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 2004; 10: 7199-7206.
5. Chen Y, Yu DC, Charlton D, Henderson DR. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000; 11: 1553-1567.
6. Guse K, Ranki T, Ala-Opas M, et al. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol Cancer Ther 2007; 6: 2728-2736.
7. Guse K, Diaconu I, Rajecki M, et al. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Ther 2009; 16: 1009-1020.
8. Mastrangeli A, Harvey BG, Yao J, et al. 'Sero-switch' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996; 7: 79-87.
9. Mack CA, Song WR, Carpenter H, et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99-109.
10. Blackwell JL, Li H, Gomez-Navarro J, et al. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum Gene Ther 2000; 11: 1657-1669.
11. Hemminki A, Belousova N, Zinn KR, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001; 4: 223-231.
12. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
13. Youil R, Toner TJ, Su Q, et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 2002; 13: 311-320.
14. Wang M, Hemminki A, Siegal GP, et al. Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. Gynecol Oncol 2005; 96: 341-348.
15. Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005; 174: 7179-7185.
16. Roy S, Clawson DS, Calcedo R, et al. Use of chimeric adenoviral vectors to assess capsid neutralization determinants. Virology 2005; 333: 207-214.
17. Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006; 441: 239-243.
18. Sarkioja M, Pesonen S, Raki M, et al. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther 2008; 15: 921-929.
19. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996; 70: 2116-2123.
20. Toogood CI, Crompton J, Hay RT. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol 1992; 73: 1429-1435.
21. Pichla-Gollon SL, Drinker M, Zhou X, et al. Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 2007; 81: 1680-1689.
22. Gahery-Segard H, Farace F, Godfrin D, et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 1998; 72: 2388-2397.
23. Hong SS, Habib NA, Franqueville L, Jensen S, Boulanger PA. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J Virol 2003; 77: 10366-10375.
24. Myhre S, Henning P, Granio O, et al. Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector. Gene Ther 2007; 14: 376-381.
25. Liebermann H, Lotz K, Mentel R, Bauer U, Seidel W. Mapping of linear epitopes on fibre knob of human adenovirus serotype 5. Virus Res 2001; 73: 145-151.
26. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11: 351-357.
27. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
28. Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738-5748.
29. Cripe TP, Dunphy EJ, Holub AD, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001; 61: 2953-2960.
30. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.
31. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70: 6839-6846.
32. Vanderkwaak TJ, Wang M, Gomez-Navarro J, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999; 74: 227-234.
33. Kangasniemi L, Kiviluoto T, Kanerva A, et al. Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin Cancer Res 2006; 12: 3137-3144.
34. Sarkioja M, Kanerva A, Salo J, et al. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer 2006; 107: 1578-1588.
35. Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297-4309.
36. Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18: 1874-1884.
37. Bauerschmitz GJ, Guse K, Kanerva A, et al. Triple-targeted oncolytic adenoviruses featuring the Cox2 promoter, E1 A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006; 14: 164-174.
38. Pesonen S, Nokisalmi P, Escutenaire S, et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 2010; 17: 892-904.
39. Rojas JJ, Cascallo M, Guedan S, et al. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther 2009; 16: 1441-1451.
40. Nokisalmi P, Pesonen S, Escutenaire S, et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 2010; 16: 3035-3043.
41. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
42. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1 A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
43. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
44. Wu H, Seki T, Dmitriev I, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 2002; 13: 1647-1653.
45. Stewart PL, Chiu CY, Huang S, et al. Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO J 1997; 16: 1189-1198.
46. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120-126.
47. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-1270.
48. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652-660.
49. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-458.
50. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-1504.
51. Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol 1988; 62: 2321-2328.
52. Wang H, Li ZY, Liu Y, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011; 17: 96-104.
53. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8: 89-98.
54. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007; 7: 141-148.
55. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 2002; 9: 979-986.
56. Leen AM, Sili U, Vanin EF, et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 2004; 104: 2432-2440.
57. Tang J, Olive M, Pulmanausahakul R, et al. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 2006; 350: 312-322.
58. Leen AM, Christin A, Khalil M, et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2008; 82: 546-554.
59. Alemany R. A smart move against cancer for vaccinia virus. Lancet Oncol 2008; 9: 507-508.
60. Tuve S, Liu Y, Tragoolpua K, et al. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine 2009; 27: 4225-4239.